ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
This specialty pharma company, known for its branded and generic drug portfolio, just reported a notable insider sale in the latest filing.
Overview
Stephen Carey, SVP & CFO of ANI Pharmaceuticals (NASDAQ:ANIP), reported the sale of 2,850 shares of common stock in an open-market transaction on June 29, according to a SEC Form 4 filing.
The transaction and post-transaction values based on June 29, 2026 market close price of $84.12.
Details
* 1-year performance calculated using June 29th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.